Loading quotes...

Forecast

The analysts' average price target is €14.69 (+71.81%). The median is €16.10 (+88.30%).

Buy	15
Hold	4
Sell	0

News Go to news feed

Verastem presents two-pronged strategy with growing CO-PACK sales and G12D pipeline

Verastem signals an improved commercial rollout of its CO-PACK product with rising patient acquisition and retention, particularly in low‑grade serous ovarian cancers, and estimates the market potential at $200–800 million. In parallel, the company is advancing its G12D inhibitor, which has already been used in more than 200 patients in Verastem’s own studies (plus >300 with partner GenFleet); key phase I/II data are expected to be presented on October 14. Verastem sees the molecule as advantageous versus competitors thanks to a dual on/off mechanism, long target residence time and high selectivity, and plans FDA discussions in 2024 as well as potential phase III starts in H1 2025. The Oberland financing strengthens liquidity, and management is seeking partnerships to continue development in a non‑dilutive manner. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Verastem Inc has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Verastem Inc had revenue of €35.12m and net profit of -€30.38m

(EUR)	June 2026	YoY
Revenue	35.12m	1,836.86%
Gross profit	31.58m	2,100.91%
Net profit	-30.38m	38.08%
EBITDA	-29.11m	34.04%

Fundamentals

Metric	Value
Market capitalization	€789.56m
Number of shares	90.56m
52-week high/low	€9.68 - €3.07
Dividends	No
Beta	0.32
P/E ratio	-3.96
PEG ratio	-0.16
P/B ratio	19.53
P/S ratio	10.09

Company profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.